Sionna Therapeutics Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Sionna Therapeutics Inc.
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Waltham
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
SION
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0002036042

Board of directors

Follow this board

Chief executives

Michael Cloonan · President & CEO
Dates unknown

Director election results

Annual meeting of June 17, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

11 of this board's directors also sit on 37 other boards.

Network of Sionna Therapeutics Inc.'s board connections ARS Pharmaceuticals Inc. ARS Pharmaceuticals In... Jade Biosciences Inc. Jade Biosciences Inc. LENZ Therapeutics Inc. LENZ Therapeutics Inc. PepGen Inc. PepGen Inc. Vor Biopharma Inc. Vor Biopharma Inc. Acrivon Therapeutics Inc. Acrivon Therapeutics I... Acumen Pharmaceuticals Inc. Acumen Pharmaceuticals... Artiva Biotherapeutics Inc. Artiva Biotherapeutics... Bicara Therapeutics Inc. Bicara Therapeutics In... Black Diamond Therapeutics Inc. Black Diamond Therapeu... Climb Bio Inc. Climb Bio Inc. Evommune Inc. Evommune Inc. Freenome Inc. Freenome Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... Janux Therapeutics Inc. Janux Therapeutics Inc... Mineralys Therapeutics Inc. Mineralys Therapeutics... Joanne L. Viney Joanne L. Viney Joshua Resnick Joshua Resnick Peter A. Thompson Peter A. Thompson Peter Kolchinsky Peter Kolchinsky Rajeev M. Shah Rajeev M. Shah Sionna Therapeutics Inc.
Shared director Other board Same sector +21 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$192,580,985
148 sales by 10 insiders
Date Insider Transaction Shares Price Value
Sep 17, 2026 Michael Cloonan Director, Officer (President & CEO) Grant or award +109,025 — —
Sep 17, 2026 Fitzpatrick Jennifer Officer (CLO and Head of Program Mgmt.) Grant or award +28,133 — —
Sep 17, 2026 McKee Charlotte Officer (CMO and Head of R&D) Grant or award +50,000 — —
Sep 17, 2026 Elena Ridloff Officer (CFO and CBO) Grant or award +47,269 — —
Sep 17, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market sale −3,415,011 $6.32 $21,582,870
Sep 17, 2026 Michael Cloonan Director, Officer (President & CEO) Grant or award +109,025 — —
Sep 17, 2026 Fitzpatrick Jennifer Officer (CLO and Head of Program Mgmt.) Grant or award +28,132 — —
Sep 17, 2026 McKee Charlotte Officer (CMO and Head of R&D) Grant or award +50,000 — —
Sep 17, 2026 Elena Ridloff Officer (CFO and CBO) Grant or award +47,268 — —
Sep 17, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market sale −33,800 $7.46 $252,148
Jul 7, 2026 ORBIMED ADVISORS LLC Director Open-market sale −85,918 $44.86 $3,854,281
Jul 7, 2026 Peter A. Thompson Director Open-market sale −85,918 $44.86 $3,854,281
Jul 6, 2026 Fitzpatrick Jennifer Officer (Chief Legal Officer) Option exercise +10,250 $6.11 $62,628
Jul 6, 2026 Fitzpatrick Jennifer Officer (Chief Legal Officer) Open-market sale −10,250 $43.60 $446,862
Jun 30, 2026 ORBIMED ADVISORS LLC Director Open-market sale −115,844 $45.50 $5,270,902

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.